Related Experiment Videos
Experimental metastasis inhibition by pretreatment of the host
1I. Institute of Pathology and Experimental Cancer Research Semmelweis Medical University, Budapest, Hungary.
Abstract:
In an experimental murine metastasis model host pretreatment protocol (HPP) was tested to abrogate lung colonization of tumor cells. The stimulation of the host defense by lentinan or TP4, and the PGI2 administration was effective in the case of the immunosensitive low metastatic tumor. The modulation of the host cells and/or the extracellular matrix by the glycosaminoglycan biosynthesis blocking agent KL-103--but not by the degradation inhibitor suramin--inhibited the lung colonization of the highly metastatic immunoresistant tumor variant. In combination with the cytotoxic antiproliferative agents these non-toxic drugs could be useful in new protocols to prevent tumor dissemination.
Insights
Host pretreatment protocols (HPP) can prevent tumor cell lung colonization. Immune stimulation worked for low-metastatic tumors, while matrix modulation drugs like KL-103 were effective against highly metastatic variants.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Tumor cell metastasis, particularly lung colonization, remains a significant challenge in cancer treatment.
- Existing therapies often struggle with highly metastatic and immunoresistant tumor variants.
- Novel strategies are needed to prevent cancer dissemination and improve patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of a host pretreatment protocol (HPP) in abrogating lung colonization of tumor cells in a murine model.
- To investigate the differential effects of immune-stimulating agents and extracellular matrix modulators on tumor metastasis.
- To identify potential non-toxic therapeutic agents for preventing tumor dissemination.
Main Methods:
- Utilized an experimental murine metastasis model to assess lung colonization.
- Administered lentinan, TP4, and PGI2 to stimulate host defense mechanisms.
- Applied the glycosaminoglycan biosynthesis inhibitor KL-103 and the degradation inhibitor suramin to modulate host cells and extracellular matrix.
- Tested combination therapies with cytotoxic antiproliferative agents.
Main Results:
- Host defense stimulation (lentinan, TP4, PGI2) was effective against immunosensitive, low-metastatic tumors.
- KL-103, a glycosaminoglycan biosynthesis inhibitor, effectively inhibited lung colonization of highly metastatic, immunoresistant tumor variants.
- Suramin, an extracellular matrix degradation inhibitor, did not show similar inhibitory effects.
- KL-103 demonstrated efficacy in modulating host cells and/or extracellular matrix.
Conclusions:
- Host pretreatment protocols can be tailored to target different tumor metastatic potentials.
- KL-103 shows promise as a non-toxic agent for inhibiting metastasis in aggressive cancers.
- Combining non-toxic drugs like KL-103 with cytotoxic agents may offer a novel strategy for preventing tumor dissemination.